Glen Eagle Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $43.3K | Sell |
1,179
-265
| -18% | -$12.6K | 0.01% | 464 |
|
|
2025
Q4 | $73.5K | Sell |
1,444
-758
| -34% | -$38.8K | 0.01% | 375 |
|
|
2025
Q3 | $122K | Sell |
2,202
-3,492
| -61% | -$204K | 0.02% | 310 |
|
|
2025
Q2 | $393K | Sell |
5,694
-1,625
| -22% | -$111K | 0.06% | 177 |
|
|
2025
Q1 | $508K | Sell |
7,319
-4,149
| -36% | -$343K | 0.08% | 144 |
|
|
2024
Q4 | $986K | Sell |
11,468
-260
| -2% | -$28.1K | 0.16% | 96 |
|
|
2024
Q3 | $1.4M | Buy |
11,728
+1,103
| +10% | +$147K | 0.24% | 77 |
|
|
2024
Q2 | $1.52M | Buy |
10,625
+1,591
| +18% | +$211K | 0.28% | 66 |
|
|
2024
Q1 | $1.16M | Buy |
9,034
+1,281
| +17% | +$152K | 0.22% | 87 |
|
|
2023
Q4 | $802K | Sell |
7,753
-3,726
| -32% | -$368K | 0.17% | 106 |
|
|
2023
Q3 | $1.04M | Buy |
11,479
+9,105
| +384% | +$802K | 0.24% | 85 |
|
|
2023
Q2 | $192K | Buy |
2,374
+2,332
| +5,552% | +$191K | 0.04% | 231 |
|
|
2023
Q1 | $3.34K | Sell |
42
-4
| -9% | -$284 | ﹤0.01% | 781 |
|
|
2022
Q4 | $3.11K | Buy |
+46
| New | +$2.7K | ﹤0.01% | 807 |
|
|
2022
Q2 | – | Sell |
-26
| Closed | -$1.44K | – | 1020 |
|
|
2022
Q1 | $1.44K | Sell |
26
-200
| -88% | -$10.3K | ﹤0.01% | 847 |
|
|
2021
Q4 | $12.7K | Sell |
226
-774
| -77% | -$41.9K | ﹤0.01% | 582 |
|
|
2021
Q3 | $48K | Hold |
1,000
| – | – | 0.01% | 381 |
|
|
2021
Q2 | $41.9K | Hold |
1,000
| – | – | 0.01% | 409 |
|
|
2021
Q1 | $33.7K | Hold |
1,000
| – | – | 0.01% | 412 |
|
|
2020
Q4 | $34.9K | Hold |
1,000
| – | – | 0.01% | 387 |
|
|
2020
Q3 | $34.7K | Sell |
1,000
-14
| -1% | -$467 | 0.02% | 359 |
|
|
2020
Q2 | $33.2K | Buy |
1,014
+14
| +1% | +$447 | 0.02% | 347 |
|
|
2020
Q1 | $30.1K | Buy |
1,000
+50
| +5% | +$1.49K | 0.02% | 333 |
|
|
2019
Q4 | $27.5K | Buy |
950
+150
| +19% | +$4.15K | 0.01% | 415 |
|
|
2019
Q3 | $20.7K | Hold |
800
| – | – | 0.01% | 404 |
|
|
2019
Q2 | $20.4K | Hold |
800
| – | – | 0.01% | 396 |
|
|
2019
Q1 | $20.9K | Hold |
800
| – | – | 0.02% | 379 |
|
|
2018
Q4 | $18.4K | Hold |
800
| – | – | 0.02% | 375 |
|
|
2018
Q3 | $18.9K | Hold |
800
| – | – | 0.01% | 386 |
|
|
2018
Q2 | $18.4K | Hold |
800
| – | – | 0.01% | 373 |
|
|
2018
Q1 | $19.7K | Sell |
800
-600
| -43% | -$15.8K | 0.02% | 344 |
|
|
2017
Q4 | $37.6K | Hold |
1,400
| – | – | 0.03% | 274 |
|
|
2017
Q3 | $33.7K | Sell |
1,400
-950
| -40% | -$21.5K | 0.03% | 279 |
|
|
2017
Q2 | $50.4K | Hold |
2,350
| – | – | 0.04% | 218 |
|
|
2017
Q1 | $40.3K | Buy |
2,350
+600
| +34% | +$10.4K | 0.03% | 220 |
|
|
2016
Q4 | $31.4K | Buy |
+1,750
| New | +$31.7K | 0.03% | 240 |
|
Other funds holding NVO
DAM
F
Glen Eagle Advisors's NVO Position: Q1 2026 in Review
Glen Eagle Advisors reduced its Novo Nordisk (NVO) stake by 18% in Q1 2026, selling an estimated $12.6K and leaving 1,179 shares worth $43.3K. The position accounts for 0.01% of the portfolio, ranked #464.
Glen Eagle Advisors first reported a position in NVO in Q4 2016 and has held it in 36 quarters since. The position peaked at $1.52M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Glen Eagle Advisors held 1,179 shares of Novo Nordisk worth $43.3K as of Q1 2026.
- Glen Eagle Advisors sold 265 Novo Nordisk shares in Q1 2026, an estimated $12.6K.
- Novo Nordisk made up 0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #464 holding.
- Glen Eagle Advisors first reported a position in Novo Nordisk in Q4 2016 and has held it in 36 quarters since.
- Glen Eagle Advisors's Novo Nordisk position peaked at $1.52M in Q2 2024.
- 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.